Today at the AgVocacy Forum in New Orleans, Bayer recognized the 2016 Young Farmer Sustainability Award and Produce Innovation Award winners. The Young Farmer Sustainability Award was presented to Tyler Wegmeyer of Wegmeyer Farms, a commercial wholesale, u-pick and agritourism operation in northern Virginia. Amy Machamer and Hurd Orchards, a family-owned fruit farm in upstate New York, received the Produce Innovation Award.
“We are proud to recognize two farmers who are committed to modern, sustainable agriculture and focused on strengthening the public’s connection with agriculture,” said Jim Blome, president and CEO of Bayer CropScience LP. “It’s an honor to work alongside people who are so passionate about their profession and dedicated to making a difference in the lives of others.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7452955-bayer-agvocacy-forum-awards/
https://thetruthaboutketosis.com/
The Ketogenic diet or Keto Diet is not a diet fad or a new diet. Although over the last few years the Keto Diet has received a lot of attention, both positive and negative, the Keto Diet has been around for almost one hundred years.
Keto was created by doctors in 1924 to treat epilepsy, and more recently has been studied as a treatment for diabetes.
Keto really works and has unbelievable health benefits, besides weight loss, that you will notice in a short period of time.
Boston Scientific (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) approval for the SYNERGY™ Bioabsorbable Polymer Drug-Eluting Stent System (BP-DES) for the treatment of coronary artery disease.
With this FDA approval, Boston Scientific will commence commercialization of the first and only BP-DES in the U.S. Notably, both the drug coating and the polymer – which modulates drug release – are fully absorbed shortly after drug elution is complete at three months.
The SYNERGY Stent provides synchronized drug and polymer absorption. It is designed to enable more rapid and complete arterial healing, and to thereby reduce the risk of complications associated with long-term polymer exposure compared to currently-used drug-eluting stents (DES) with permanent polymers.
To view the multimedia release go to:
http://www.multivu.com/players/English/7223456-boston-scientific-fda-approval-synergy/
Oklahoma State University’s planned performing arts center received a major boost today with a $25 million gift from alumni Ross and Billie McKnight to establish an endowment to support programming.
“This visionary gift from the McKnights will ensure our new performing arts center truly maximizes the opportunities for cultural enrichment that the magnificent modern facility will afford,” said Oklahoma State University President Burns Hargis. “As a result of the generosity of the McKnights, we will be available to present celebrated national and international performing arts productions and artists that will enhance the cultural experience on campus, in the Stillwater community and across the region.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7797251-osu-mcknight-center-performing-arts/
EnteroMedics Inc. (NASDAQ: ETRM) today announced that the U.S. Food and Drug Administration (FDA) has approved VBLOC® vagal blocking therapy, delivered via the Maestro® System, for the treatment of adult patients with obesity who have a Body Mass Index (BMI) of at least 40 to 45 kg/m2, or a BMI of at least 35 to 39.9 kg/m2 with a related health condition such as high blood pressure or high cholesterol levels, and who have tried to lose weight in a supervised weight management program within the past five years. The Maestro System is the first new medical device to be approved by the FDA for obesity in over ten years. EnteroMedics anticipates that the device will be available, on a limited basis, at select Bariatric Centers of Excellence in the U.S. this year. The Maestro System has received CE Mark and is listed on the Australian Register of Therapeutic Goods.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7269351-enteromedics-fda-approval-vbloc-maestro-system-weight-loss-device/
Ashok Leyland, flagship of the Hinduja Group, today received the prestigious 2016 Deming Prize for its Pantnagar manufacturing facility. The Deming Prize is a global quality award and is the oldest and most widely recognized quality award in the world. This prize is awarded to companies that have established Total Quality Management (TQM) in their business operations. Ashok Leyland Pantnagar has become the first truck and bus plant in the world and also the only CV manufacturer outside of Japan to win the Deming Prize.
To view the multimedia release go to:
http://www.multivu.com/players/uk/7980351-ashok-leyland-deming-prize/
The JNA Awards proudly announced its highly anticipated list of Honourees or finalists across 10 categories on the sidelines of the June Hong Kong Jewellery & Gem Fair.
The event, now in its sixth year, is a premier awards programme that recognises and celebrates excellence and achievement in the jewellery and gemstone industry, with a focus on advancing the trade in Asia.
This year, close to 100 highly qualified entries from 13 countries and regions, namely mainland China, Fiji, Hong Kong, India, Japan, Malaysia, Singapore, South Korea, Switzerland, Taiwan, Thailand, United Arab Emirates and Vietnam, were received.
To view the multimedia release go to:
https://www.multivu.com/players/English/8126151-jna-awards-2017/
Today, Novo Nordisk announced a three-year extension of its Changing Diabetes® in Children programme. Since 2009, free insulin and access to diabetes care have been provided to more than 13,000 children in nine countries in Africa and South-East Asia. During the five years, 108 diabetes clinics have been established and 5,479 healthcare professionals have received diabetes care training.
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7496851-novo-nordisk-children-with-diabetes/
Johnson Controls, a global, multi-industry company, received this year’s CLEPA Innovation Award in the category “Green” for its cutting-edge work in the CAMISMA research project. Together with project partners from industry and science, the Johnson Controls team, working with a newly developed seat structure, succeeded in drastically reducing the use of steel and light alloys by replacing them with multi-material systems.
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7388851-johnson-controls-camisma-lightweight/
..and we have a winner people! One of the best video reviews for Freebug.co.uk that we received.. the UKs first 100% cashback site!. I'll have what she's had please!
Studies show that more than two-thirds of aesthetically-oriented consumers are bothered by submental fullness, or “double chin.” And with social media profile images becoming more important than ever, there is interest in looking one’s best.
Submental fullness due to fat beneath the chin can impact a broad range of both men and women and because the condition can be genetic and resistant to diet and exercise. But there’s KYBELLA®, the first and only FDA-approved injectable treatment that is available by prescription only, that has been proven to improve the appearance of moderate to severe fat beneath the chin by physically destroying fat cells in the treatment area. In two pivotal clinical studies for KYBELLA®, reductions in submental fat volume were observed more frequently in the KYBELLA® treated group of 514 patients compared to the placebo group (508 patients) as measured by both clinician and patient ratings. In addition, visual and emotional impacts of submental fat (happy, bothered, self-conscious, embarrassed, looking older or overweight) were evaluated using a 6-question survey and 79% of 1 and 2-grade composite responders reported satisfaction after 12 weeks post final treatment compared with 33.6% of patients who received placebo.
To view the multimedia release go to:
http://www.multivu.com/players/English/7962051-kybella-injectable-double-chin-treatment-campaign/
Today, Novo Nordisk announced a four-year extension of its Changing Diabetes® in Children programme which provides access to diabetes care and free insulin to children with type 1 diabetes in developing countries. The expansion sees five new countries join the programme; Cambodia, Ivory Coast, Myanmar, Senegal and Sudan. By 2020, more than 20,000 children over the course of 11 years will have benefited from the programme.
Ten years ago, a child in Sub-Saharan Africa diagnosed with type 1 diabetes often had a life expectancy of less than a year1. In response, Novo Nordisk established the Changing Diabetes® in Children programme to support sustainable quality care and improved diagnosis of the condition. Since the start of the programme in 2009, 13,700 children in nine countries in Africa and South-East Asia have received free human insulin and access to diabetes care.
To view the multimedia release go to:
http://www.multivu.com/players/uk/7962351-novo-nordisk-programme-children-diabetes/
